Exelixis, Inc. financial data

Symbol
EXEL on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
1851 Harbor Bay Parkway, Alameda, CA
Fiscal year end
January 3
Latest financial report
10-Q - Q1 2025 - May 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 382 % +0.37%
Quick Ratio 5.76 % -7.09%
Debt-to-equity 31.3 % +11.8%
Return On Assets 22.4 % +223%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 273M shares -6.38%
Common Stock, Shares, Outstanding 275M shares -6.78%
Entity Public Float 4.8B USD +2.13%
Common Stock, Value, Issued 275K USD -6.78%
Weighted Average Number of Shares Outstanding, Basic 279M shares -7.3%
Weighted Average Number of Shares Outstanding, Diluted 288M shares -5.68%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 2.3B USD +24.5%
Research and Development Expense 895M USD -13.7%
Costs and Expenses 1.54B USD -8.25%
Operating Income (Loss) 762M USD +344%
Income Tax Expense (Benefit) 194M USD +264%
Net Income (Loss) Attributable to Parent 644M USD +214%
Earnings Per Share, Basic 2.25 USD/shares +246%
Earnings Per Share, Diluted 2.19 USD/shares +237%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 184M USD -29.2%
Marketable Securities, Current 848M USD
Inventory, Net 24.9M USD +17.8%
Assets, Current 1.4B USD +8.05%
Deferred Income Tax Assets, Net 419M USD +15.9%
Property, Plant and Equipment, Net 115M USD -9.58%
Operating Lease, Right-of-Use Asset 173M USD -26%
Goodwill 63.7M USD 0%
Assets 2.84B USD +1.2%
Accounts Payable, Current 42.8M USD +64.3%
Contract with Customer, Liability, Current 2.87M USD -29.1%
Liabilities, Current 399M USD +7%
Contract with Customer, Liability, Noncurrent 3.09M USD -37.3%
Operating Lease, Liability, Noncurrent 187M USD -7.12%
Other Liabilities, Noncurrent 120M USD +18.5%
Liabilities 706M USD +4.51%
Accumulated Other Comprehensive Income (Loss), Net of Tax 2.01M USD
Retained Earnings (Accumulated Deficit) -163M USD +36.9%
Stockholders' Equity Attributable to Parent 2.13B USD +0.14%
Liabilities and Equity 2.84B USD +1.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 211M USD +207%
Net Cash Provided by (Used in) Financing Activities -295M USD -60.2%
Net Cash Provided by (Used in) Investing Activities 49.8M USD -55.5%
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 275M shares -6.78%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -33.6M USD -879%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 184M USD -29.2%
Deferred Tax Assets, Valuation Allowance 86M USD +3.65%
Deferred Tax Assets, Gross 545M USD +9.46%
Operating Lease, Liability 216M USD +0.08%
Payments to Acquire Property, Plant, and Equipment 2.95M USD -69.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 651M USD +211%
Lessee, Operating Lease, Liability, to be Paid 286M USD -9.46%
Property, Plant and Equipment, Gross 220M USD +5.26%
Operating Lease, Liability, Current 25M USD -2.74%
Lessee, Operating Lease, Liability, to be Paid, Year Two 28.5M USD +11.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 26.5M USD +0.7%
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 69.9M USD -11.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 24.3M USD -7.2%
Deferred Tax Assets, Operating Loss Carryforwards 39.9M USD +35.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 128M USD +10.1%
Lessee, Operating Lease, Liability, to be Paid, Year Four 25M USD -7.19%
Additional Paid in Capital 2.29B USD -4.17%
Depreciation, Depletion and Amortization 7.35M USD +15.2%
Deferred Tax Assets, Net of Valuation Allowance 459M USD +10.6%
Share-based Payment Arrangement, Expense 101M USD -7.49%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%